Ph.D., CEO and Co-founder, Director of Twist Bioscience
Emily Leproust, Ph.D. serves as CEO, co-founder and director of Twist Bioscience. Dr. Leproust is disrupting the process of gene synthesis to enable the exponential growth of synthetic biology applications in multiple fields including medicine, DNA data storage, agricultural biology and industrial chemicals. In 2015, she was named one of Foreign Policy’s 100 Leading Global Thinkers of 2015 and Fast Company named her one of the most creative people in business. Prior to Twist Bioscience, she held escalating positions at Agilent Technologies where she architected the successful SureSelect product line that lowered the cost of sequencing and elucidated dozens of Mendelian diseases.
Rewriting DNA Synthesis
The applications enabled by perfect DNA sequences from a highly scalable synthesis platform are limitless. With innovative silicon-based platforms, reaction volumes are miniaturized by a factor of 1000 enabling high quality DNA production at reduced price and turn-around time. Delivering DNA as genes, ready-to-use oligonucleotide pools or variant libraries simplifies experiments by circumventing the need to clone, allowing use of sequence space to be reimagined on a grander scale, ultimately accelerating discoveries.
Session Abstract – PMWC 2017 Silicon Valley
Session Synopsis: Innovative new technologies continue to evolve and improve. Whether it is repurposing DNA to store digital data, improving the analysis of metabolites in biological specimen, or the advancements in analyzing and visualizing single cell data, these new emerging fields are driving precision medicine into the future.